Armata Pharmaceuticals Q2 2024 Earnings Report $2.11 +0.10 (+4.98%) As of 02/21/2025 04:10 PM Eastern Earnings HistoryForecast Armata Pharmaceuticals EPS ResultsActual EPS-$0.65Consensus EPS -$0.52Beat/MissMissed by -$0.13One Year Ago EPSN/AArmata Pharmaceuticals Revenue ResultsActual RevenueN/AExpected RevenueN/ABeat/MissN/AYoY Revenue GrowthN/AArmata Pharmaceuticals Announcement DetailsQuarterQ2 2024Date8/13/2024TimeN/AConference Call ResourcesARMP Earnings History Armata Pharmaceuticals Earnings HeadlinesPromising Phase 2 Results for AP-PA02 Boost Armata Pharmaceuticals’ Investment AppealDecember 22, 2024 | markets.businessinsider.comArmata Pharma’s inhaled AP-PA02 shows positive results in Phase 2 studyDecember 20, 2024 | finance.yahoo.comA strange twist 500 miles from WashingtonEnergy is life. And this year, it could also make national heroes out of President Trump and VP Vance. With the news cycle dominated by the tariffs… Elon’s DOGE… and the Russia peace talks… Hidden in America's forgotten towns, a groundbreaking energy discovery is taking shape. And it's happening right in our own backyard – in the heart of Appalachia.February 22, 2025 | Porter & Company (Ad)Armata Pharmaceuticals Announces Encouraging Results from the Phase 2 Tailwind Study of Inhaled AP-PA02 in Non-Cystic Fibrosis Bronchiectasis Subjects with Chronic Pulmonary Pseudomonas aeruginosa InfectionDecember 19, 2024 | prnewswire.comSuparna Mishra SarkarDecember 16, 2024 | latimes.comArmata Pharmaceuticals Announces CMO Departure AgreementDecember 5, 2024 | markets.businessinsider.comSee More Armata Pharmaceuticals Headlines Get Earnings Announcements in your inboxWant to stay updated on the latest earnings announcements and upcoming reports for companies like Armata Pharmaceuticals? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Armata Pharmaceuticals and other key companies, straight to your email. Email Address About Armata PharmaceuticalsArmata Pharmaceuticals (NYSEAMERICAN:ARMP), a clinical-stage biotechnology company, focuses on the development of targeted bacteriophage therapeutics for antibiotic-resistant infections worldwide. It develops its products using its proprietary bacteriophage-based technology. The company's product candidates include AP-SA02 for the treatment of Staphylococcus aureus bacteremia; AP-PA02 for Pseudomonas aeruginosa; and AP-PA03 for the treatment of pneumonia. It has research collaboration agreement with Merck Sharp & Dohme Corp. for developing synthetic bacteriophage candidates to target undisclosed infectious disease agents. The company is headquartered in Los Angeles, California.View Armata Pharmaceuticals ProfileRead more More Earnings Resources from MarketBeat Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Earnings By Country U.S. Earnings Reports Canadian Earnings Reports U.K. Earnings Reports Latest Articles The Trade Desk Crashes on Earnings, But Growth Catalysts PersistHims & Hers Earnings Could Be a Game Changer—What to Do NowAnalysts See Buying Opportunity in NVIDIA Before EarningsAirbnb's Earnings: Sky High Results, Grounded Guidance?Is Coinbase Stock a Buy After Earnings?CVS Health: Earnings Beat Ignites Stock RallyQualcomm’s Post-Earnings Dip: A Prime Buying Opportunity? Upcoming Earnings Workday (2/24/2025)Intuit (2/25/2025)American Tower (2/25/2025)Bank of Montreal (2/25/2025)Bank of Nova Scotia (2/25/2025)Public Storage (2/25/2025)NVIDIA (2/26/2025)Synopsys (2/26/2025)Salesforce (2/26/2025)Lowe's Companies (2/26/2025) Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
